IC regimens and responses after HMA and VEN by HMA/VEN response
| . | All . | HMA/VEN response . | P . | |
|---|---|---|---|---|
| Refractory . | Relapse . | |||
| All | 46 (100) | 32 (70) | 14 (30) | |
| IC regimen∗ , n (%) | ||||
| 7 + 3 | 9 (20) | 8 (25) | 1 (7) | .31 |
| Liposomal daunorubicin/cytarabine | 7 (15) | 5 (16) | 2 (14) | |
| FLAG | 2 (4) | 2 (6) | 0 (0) | |
| FLAG-IDA | 14 (30) | 9 (28) | 5 (36) | |
| GCLAC | 2 (4) | 0 (0) | 2 (14) | |
| HiDAC | 2 (4) | 1 (3) | 1 (7) | |
| MEC | 10 (22) | 7 (22) | 3 (21) | |
| Response, n (%) | ||||
| CR | 9 (20) | 4 (13) | 5 (36) | 0.25 |
| CRi | 4 (9) | 2 (6) | 2 (14) | |
| MLFS | 4 (9) | 3 (9) | 1 (7) | |
| NR | 26 (57) | 20 (63) | 6 (43) | |
| Not assessed | 3 (7) | 3 (9) | 0 (0) | |
| CR/CRi/MLFS, n (%) | 17 (37) | 9 (28) | 8 (57) | .10 |
| CR/CRi, n (%) | 13 (28) | 6 (19) | 7 (50) | .04 |
| CR/CRi MRD negative, n (%) | 6 (13) | 3 (9) | 3 (21) | .35 |
| OS, median (95% CI), mo | 7.2 (5-10.3) | 5.4 (3.2-14.1) | 8.8 (5.8 to NA) | .64 |
| . | All . | HMA/VEN response . | P . | |
|---|---|---|---|---|
| Refractory . | Relapse . | |||
| All | 46 (100) | 32 (70) | 14 (30) | |
| IC regimen∗ , n (%) | ||||
| 7 + 3 | 9 (20) | 8 (25) | 1 (7) | .31 |
| Liposomal daunorubicin/cytarabine | 7 (15) | 5 (16) | 2 (14) | |
| FLAG | 2 (4) | 2 (6) | 0 (0) | |
| FLAG-IDA | 14 (30) | 9 (28) | 5 (36) | |
| GCLAC | 2 (4) | 0 (0) | 2 (14) | |
| HiDAC | 2 (4) | 1 (3) | 1 (7) | |
| MEC | 10 (22) | 7 (22) | 3 (21) | |
| Response, n (%) | ||||
| CR | 9 (20) | 4 (13) | 5 (36) | 0.25 |
| CRi | 4 (9) | 2 (6) | 2 (14) | |
| MLFS | 4 (9) | 3 (9) | 1 (7) | |
| NR | 26 (57) | 20 (63) | 6 (43) | |
| Not assessed | 3 (7) | 3 (9) | 0 (0) | |
| CR/CRi/MLFS, n (%) | 17 (37) | 9 (28) | 8 (57) | .10 |
| CR/CRi, n (%) | 13 (28) | 6 (19) | 7 (50) | .04 |
| CR/CRi MRD negative, n (%) | 6 (13) | 3 (9) | 3 (21) | .35 |
| OS, median (95% CI), mo | 7.2 (5-10.3) | 5.4 (3.2-14.1) | 8.8 (5.8 to NA) | .64 |
95% CI, 95% confidence interval.
7 + 3, daunorubicin + cytarabine; FLAG, fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor [G-CSF]; FLAG-IDA, FLAG + idarubicin; GCLAC, G-CSF, clofarabine, and cytarabine; HiDAC, high-dose cytarabine; MEC, mitoxantrone, etoposide, cytarabine.